This week’s round-up includes two pieces continuing to expand the views on how machine learning and artificial intelligence can affect cardiac care, as well as an update on the ORION-1 trial, and a negative link between non-steroidal anti-inflammatory drug (NSAIDs) and hypertension in a specific patient population.
A new study showed that automated machine learning sped up the assessment of cardiac MRI. How fast is fast? The researchers, publishing in the Journal of the American Heart Association, reported that automated cardiac MRI analysis was performed 186x faster than would have been performed by human readers.
Inclisiran, dosed infrequently, was associated with a decrease in LDL-C levels, providing an option for patients who have difficultly adhering to more frequently administered LDL-C-lowering medication regimens. Specifically, this analysis of the one-year results of the ORION-1 study published in JAMA Cardiology showed that in patients who received single and double doses of inclisiran had reduced LDL-C levels over one year. “Through potent and durable lowering of LDL-C with a twice-a-year dosing regimen, inclisiran could offer a sustained lipid-lowering therapeutic option in the future,” the researchers wrote.
A British team of researchers has used artificial intelligence (AI) to uncover and identify genes linked to heart failure. According to their new paper in Circulation, MRI images from more than 17,000 health volunteers in the UK Biobank database shod that 22% to 39% of the variation in size and function of the left ventricle was determined by genetic factors. “The AI tool allowed us to analyse images in a fraction of the time it would otherwise have taken,” one of the researchers wrote.
The continuous use of NSAIDs in patients with ankylosing sponsylitis (AS) could result in high blood pressure, according to a new study published in Arthritis Care and Research. The study included more than 600 patients with AS without baseline hypertension. The researchers concluded that continuous NSAID use was associated with increased incidence of hypertension in those without prior hypertension, stating that future studies should “focus on precision medicine and predicting risk and benefit for patients in whom continuous NSAIDs are being considered.”